• Bionyra Pharma launched with a USD 165 million oversubscribed Series A to advance next-generation biologics for immune-mediated inflammatory diseases.
• Round was co-led by Jeito Capital, Sofinnova Partners; Sanofi Ventures joined alongside other investors.
• Company develops clinical, IND-stage mono, multispecific antibodies with half-life extension; lead programs target IBD, atopic dermatitis.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sanofi Ventures published the original content used to generate this news brief on June 22, 2026, and is solely responsible for the information contained therein.